Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?
1Global Product Development, Neuroscience, PPD, Morrisville, NC, USA.
Abstract:
Efforts to develop new therapies to combat Alzheimer's disease suffer from extraordinarily high failure rates that make it difficult to justify continued investment in the field. Although there are a number of plausible explanations for this extremely high attrition rate, one of the explanations that has received little attention is the lack of compelling data from Phase II studies for compounds that have been pushed into Phase III trials and then have failed. An analysis of publicly available data from the Phase II studies for bapineuzumab and solanezumab indicates that neither compound produced compelling evidence of drug-like behavior that would justify their progression into pivotal trials. The published data suggest that sponsors took decisions to move these compounds into Phase III on the basis of vastly limited data that were rife with type I error and probably driven by commercial concerns. The continued push to move compounds that are not likely to succeed in later stage clinical trials threatens to erode trust in the clinical research enterprise making it much harder to properly test truly promising compounds.
Insights
Alzheimer's drug development faces high failure rates. Analysis of Phase II data for bapineuzumab and solanezumab suggests insufficient evidence to justify Phase III trials, potentially due to commercial interests.
Area of Science:
- Neuroscience and Drug Development
- Clinical Trial Analysis
Background:
- High attrition rates in Alzheimer's disease (AD) drug development pose significant challenges.
- Lack of compelling Phase II data for compounds progressing to Phase III is an under-examined factor.
- Previous AD drug candidates have demonstrated exceptionally high failure rates in late-stage trials.
Purpose of the Study:
- To analyze publicly available Phase II data for bapineuzumab and solanezumab.
- To assess whether the data justified progression into Phase III clinical trials.
- To investigate potential reasons for advancing compounds with limited efficacy signals.
Main Methods:
- Retrospective analysis of published Phase II clinical trial data for bapineuzumab and solanezumab.
- Evaluation of the strength of evidence for drug-like behavior and efficacy signals.
- Assessment of potential biases, including Type I error and commercial influences, in decision-making.
Main Results:
- Neither bapineuzumab nor solanezumab demonstrated compelling drug-like behavior in Phase II studies.
- The available data were insufficient to robustly support progression to Phase III trials.
- Decisions to advance these compounds may have been influenced by limited data and commercial considerations.
Conclusions:
- The progression of bapineuzumab and solanezumab into Phase III trials was not adequately supported by Phase II data.
- Overemphasis on limited or potentially erroneous data risks eroding trust in clinical research.
- Rigorous evaluation of Phase II results is crucial for efficient and ethical advancement of Alzheimer's therapeutics.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests